Compare LUNR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNR | TYRA |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | LUNR | TYRA |
|---|---|---|
| Price | $16.50 | $25.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $15.00 | ★ $32.17 |
| AVG Volume (30 Days) | ★ 7.4M | 603.8K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $219,936,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $163.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $6.14 | $6.42 |
| 52 Week High | $24.95 | $25.88 |
| Indicator | LUNR | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 75.13 | 75.18 |
| Support Level | $10.16 | $22.43 |
| Resistance Level | $12.80 | $23.74 |
| Average True Range (ATR) | 1.20 | 1.38 |
| MACD | 0.50 | 0.07 |
| Stochastic Oscillator | 98.03 | 88.46 |
Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure. The Company operates in one operating segment and one reportable segment underpinned by three core pillars (delivery services, data transmission services, and infrastructure as a service) that have similar capabilities, customers, and economic characteristics. Revenue is from contracts with customers of orbital and lunar access services.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.